Table 2.

Population pharmacodynamic parameter estimates from the parallel (MOX-NA, MOX-SBP and MOX-HR; full and reduced data set) and sequential (MOX-NA-SBP and MOX-NA-HR) pharmacodynamic analysis. Values are given as the mean population estimate (± %RSE).

	MOX-NA	MOX-SBP		NA-SBP	MOX-HR		NA-HR
Data set	full	full	reduced	reduced	full	reduced	reduced
Pharmacodynamic submodel
Baseline	395	126	125	126	78	77	77
(ng l−1 – mmHg – beats min−1)	(4)	(2)	(2)	(2)	(1)	(1)	(1)
Slope (= Emax/EC50)	26	16	27.5	0.24	9.3	4.7	0.18
(%decrease/ng ml−1)	(27)	(25)	(20)	(32)	(20)	(43)	(43)
Emax	47	20	19	12	25	16	5.2
(%)	(25)	(21)	(16)	(30)	(46)	(84)	(22)
ke0	1.1	0.60	0.41	–	0.49	0.32	–
(h−1)	(65)	(46)	(22)	(21)	(47)
Covariate submodel
Baseline increase with time	2.3	–	–	–	–	–	–
(%/week)	(17)
Delay in disease progression with drug	9.8	–	–	–	–	–	–
(weeks)	(14)
Decrease in drug effect	–	4.5	5.1	5.9	6.4	5.7	6.6
(Slope) (%/week)		(27)	(17)	(29)	(16)	(29)	(5)
Diurnal baseline change – peak time	–	22:00	22:00	23:00	–	–	–
(hh:mm)		(4)	(4)	(3)
Diurnal baseline change – magnitude	–	4.3	5.3	6.3	–	–	–
100* (peak-average)/average		(20)	(15)	(18)
Statistical submodel
Inter-individual variability in Baseline	37	15	15	15	13	13	13
(%)	(7)	(7)	(7)	(7)	(8)	(9)	(9)
Inter-individual variability in Slope	110	220	147	212	120	182	444
(%)	(34)	(31)	(28)	(31)	(22)	(43)	(36)
Inter-individual variability in ke0	160	140	122	–	–	–	–
(%)	(37)	30)	(25)
Interoccasion variability in Baseline	18	6.0	6.0	5.7	5.5	6.0	6.0
(%)	(7)	(6)	(8)	(8)	(7)	(9)	(8)
Residual variability	20	8.0	7.9	8.3	5.3	5.2	5.2
(%CV – s.d.(mmHg) – s.d.(beats min−1))	(5)	(3)	(3)	(3)	(3)	(4)	(3)